Risk of Hemorrhagic Stroke in Patients With Coronavirus Disease 2019—Reply | JAMA Neurology | JAMA Network
[Skip to Navigation]
Sign In
Comment & Response
March 8, 2021

Risk of Hemorrhagic Stroke in Patients With Coronavirus Disease 2019—Reply

Author Affiliations
  • 1Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, New York, New York
JAMA Neurol. 2021;78(4):497. doi:10.1001/jamaneurol.2021.0120

In Reply We thank Dr Silverman and colleagues for their interest in our study1 and providing us the opportunity to expand on our results. Among the 1916 patients who visited the emergency department or were hospitalized with coronavirus disease 2019 (COVID-19) in our study,1 8 patients (0.4% [95% CI, 0.2%-0.8%]) had hemorrhagic stroke, including 7 with intracerebral hemorrhage and 1 with subarachnoid hemorrhage. Among these 8 patients, 4 strokes were attributed to anticoagulant use.

Regarding the question about hemorrhagic transformation, 2 of 31 patients with COVID-19 and acute ischemic stroke in our study1 had symptomatic hemorrhagic transformation. One of these was attributed to intravenous thrombolysis, while the other was attributed to therapeutic-dose anticoagulant use. Overall, 1 of 3 patients (33.3% [95% CI, 8.4%-90.6%]) with COVID-19 who were treated with intravenous thrombolysis for acute ischemic stroke in our cohort developed symptomatic hemorrhagic transformation.

We agree that a better understanding of the risks of hemorrhagic stroke in patients with COVID-19 are necessary to inform the risk-benefit assessments of intravenous thrombolysis and anticoagulant therapy for this population. Since the publication of our study,1 several studies have reported on the risk of hemorrhagic stroke in patients hospitalized with COVID-19.2,3 We did not collect data on anticoagulant use among patients with COVID-19 who did not have ischemic or hemorrhagic stroke, and therefore we are unable to evaluate the association between anticoagulant use and incident stroke in our cohort.1 We acknowledge that both prophylactic-dose and therapeutic-dose anticoagulant therapy could affect the incidence of stroke and other thromboembolic events, including by potentially causing net harm through an increase in hemorrhagic stroke. We believe that randomized clinical trials are necessary to determine the safety and efficacy of these treatments. To our knowledge, there are multiple active trials evaluating this question, including the National Institutes of Health–funded Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4) trial (NCT04505774). We eagerly await the results of ACTIV-4 and other, similar trials, which hopefully will answer the question of whether anticoagulant use in patients hospitalized with COVID-19 is beneficial.

Back to top
Article Information

Corresponding Author: Babak B. Navi, MD, MS, Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medicine, 420 E 70th St, Room 411, New York, NY 10021 (ban9003@med.cornell.edu).

Published Online: March 8, 2021. doi:10.1001/jamaneurol.2021.0120

Conflict of Interest Disclosures: Dr Merkler has received personal fees for medicolegal consulting on stroke. Dr Navi serves as a data safety monitoring board member for the Patient-Centered Outcomes Research Institute–funded Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (TRAVERSE) trial and has received personal fees for medicolegal consulting on stroke. The authors also report support from National Institutes of Health grants K23NS091395, R01HL144541, and UL1TR000457, as well as support from NewYork-Presbyterian Hospital and Weill Cornell Medical College, including their Clinical and Translational Science Center and Joint Clinical Trials Office. No other disclosures were reported.

References
1.
Merkler  AE, Parikh  NS, Mir  S,  et al.  Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza.   JAMA Neurol. 2020;77(11):1-7. doi:10.1001/jamaneurol.2020.2730PubMedGoogle ScholarCrossref
2.
Kvernland  A, Kumar  A, Yaghi  S,  et al.  Anticoagulation use and hemorrhagic stroke in SARS-CoV-2 patients treated at a New York healthcare system.   Neurocrit Care. 2020. doi:10.1007/s12028-020-01077-0PubMedGoogle Scholar
3.
Rothstein  A, Oldridge  O, Schwennesen  H, Do  D, Cucchiara  BL.  Acute cerebrovascular events in hospitalized COVID-19 patients.   Stroke. 2020;51(9):e219-e222. doi:10.1161/STROKEAHA.120.030995PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×